The pathobiology of polycystic kidney disease from a metabolic viewpoint

Area of Science:

• Nephrology
• Molecular Biology
• Metabolic Disease

Background:

• Autosomal dominant polycystic kidney disease (ADPKD) affects 1 in 1,000 individuals, often leading to end-stage renal disease (ESRD).
• Tolvaptan slows cyst growth but additional therapies targeting dysregulated pathways in cystic kidneys and livers are needed.
• Metabolic reprogramming is a key feature of cystic cells and contributes to ADPKD pathophysiology.

Purpose of the Study:

• To explore the role of metabolic reprogramming in ADPKD pathogenesis.
• To identify potential therapeutic targets within metabolic pathways implicated in ADPKD.
• To investigate the link between polycystin proteins, mitochondrial function, and cellular metabolism in ADPKD.

Main Methods:

• Review of existing literature on ADPKD, metabolic pathways, and signaling mechanisms.
• Analysis of studies linking mTOR, primary cilia, and polycystin function to cellular metabolism.
• Examination of the impact of mitochondrial dysfunction on cellular processes and immune response in ADPKD.

Main Results:

• Dysregulated metabolic pathways, including mTOR and primary ciliary signaling, are implicated in ADPKD.
• Polycystin-1 and polycystin-2 may influence cellular metabolism via direct effects on mitochondrial function.
• Mitochondrial dysfunction can alter cellular redox state, acetyl-CoA levels, gene expression, and promote fibrosis and inflammation.

Conclusions:

• Metabolic reprogramming is a critical factor in ADPKD progression.
• Targeting metabolic pathways presents a promising therapeutic avenue for ADPKD.
• Further research into the interplay between genetics, metabolism, and mitochondrial function is crucial for developing novel ADPKD treatments.